Short Summary
Paras Pharmaceuticals Ltd. filed a suit against Ranbaxy Laboratories Ltd., alleging that Ranbaxy was using negative advertisement and TV commercials for its pain reliever VOLINI to disparage Paras's popular product, MOOV. The court found that Ranbaxy's commercial depicted a box identical in artistic work and color scheme to MOOV, subtly suggesting that MOOV was inferior. Consequently, the Gujarat High Court allowed the appeal and directed Ranbaxy to change its packaging colors and cease using the appellant's artwork.
Detailed Summary
In the fiercely competitive world of over-the-counter products, brands constantly jockey for consumer attention. But what happens when a competitor's advertisement crosses the line from clever marketing into outright disparagement? The 2008 showdown between Paras Pharmaceuticals and Ranbaxy Laboratories offers a masterclass in how trademark law protects brands not just from direct copying, but from the silent, visual attacks designed to undermine them. This case is a wake-up call for every founder who thinks that simply avoiding a competitor's name is enough to stay safe.
Paras Pharmaceuticals Ltd., the maker of the popular pain reliever MOOV, found itself at the receiving end of a marketing campaign it never signed up for. The target of its frustration was Ranbaxy Laboratories Ltd., which was promoting its own pain reliever, VOLINI. Paras alleged that Ranbaxy had launched a series of negative advertisements and TV commercials specifically designed to belittle MOOV and position VOLINI as the superior choice. The crux of Paras's complaint was not that Ranbaxy had used the MOOV name, but rather that Ranbaxy's commercial depicted a box strikingly similar to MOOV's packaging—mirroring its artistic work and color scheme. The implication was unmistakable to viewers: MOOV was being portrayed as the inferior, outdated product.
Paras Pharmaceuticals argued that Ranbaxy's commercial amounted to trademark infringement and disparagement. By replicating the distinctive visual elements of MOOV's trade dress—the artwork and color combination that consumers had come to associate with the brand—Ranbaxy was effectively riding on Paras's goodwill while simultaneously tarnishing it. The visual mimicry, Paras contended, was designed to mislead the average consumer into drawing a direct comparison, subtly suggesting that MOOV was subpar. Ranbaxy, on the other hand, pushed back against the allegations, defending its advertising strategy as legitimate competitive marketing rather than infringement. The legal friction centered on a critical question: can a brand be attacked through imitation and innuendo, even when its name is never spoken?
The Gujarat High Court came down firmly on the side of Paras Pharmaceuticals. The court found that Ranbaxy's commercial had indeed depicted a box identical in artistic work and color scheme to MOOV, and that this visual replication was no accident—it was a calculated move to disparage a competitor's product while misleading consumers. The court allowed Paras's appeal and issued a clear directive: Ranbaxy was ordered to change its packaging colors and to cease using the artwork that belonged to Paras. The ruling sent a powerful message that trademark infringement is not limited to direct copying of a mark; it extends to disparagement, denigration, and the use of similar trade dress that confuses or misleads the average consumer.
For founders and brand builders, this case is a critical reminder: your intellectual property is not just your logo or your name—it is the entire visual identity your customers recognize. If you are building a brand, invest in protecting your
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in trademark matters before Gujarat High Court. Understanding the court's reasoning in Paras Pharmaceuticals Ltd. vs Ranbaxy Laboratories Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Mahesh Namkeen Pvt. Ltd.vsOm Prakash Nebhwani (Trading as: Mahesh Matar Namkeen)
Mahesh Namkeen Pvt. Ltd., a Lucknow-based company engaged in manufacturing namkeens and snacks since 1983 under the trademark 'MAHESH' (with parrot device), sued Om Prakash Nebhwani for trademark infringement and passing off. The defendant, who is the nephew of the plaintiff's director and had prior knowledge of the mark, adopted the identical 'MAHESH' mark with parrot/peacock device for his own namkeen business in Jaipur. The defendant's defense was struck off for non-filing of written statement. The court found the plaintiff's mark to be distinctive, well-established, and a well-known trademark, and held that the defendant's use constituted slavish copying amounting to infringement and passing off.
Ms Pas AgrovsM/S Krbl Limited & Anr
Ms Pas Agro has filed a petition under Section 124(1)(b)(ii) of the Trademarks Act challenging the Commercial Court's order dismissing its application to frame a preliminary issue on the invalidity of KRBL's registered trademark 'INDIA GATE' (application no. 599833). The underlying suit CS (COMM) 78/2025 was filed by KRBL against Pas Agro. The Delhi High Court issued notice, permitted deletion of respondent no.2, and granted time for filing reply and rejoinder. The substantive question of whether a preliminary issue on trademark invalidity should be framed remains pending.
Cryogas Equipment Private LimitedvsInox India Limited & Ors.
The Supreme Court disposed of a miscellaneous application seeking extension of time for the trial court to decide Trademark Suit No. 3 of 2019 between Cryogas Equipment Private Limited and Inox India Limited. As a last opportunity, the Court granted an additional six months to the concerned court to decide the suit, while expressly warning that no further extension would be entertained. The underlying dispute concerns trademark rights in the cryogenic/industrial gas equipment sector.
Mankind Consumer Products Private LimitedvsAlaina Healthcare Private Limited & A. Menarini India Private Limited
Mankind Consumer Products, the registered proprietor of the trademark ACNESTAR (Reg. No. 1352577 in Class 5) since 2005, sued Alaina Healthcare and A. Menarini India for using the marks ACNE SCAR/ACNE+SCAR/ACNESCAR on their acne scar serum product HEXILAK. The court found a prima facie case of deceptive similarity, noting that the dominant feature 'ACNE' was common and the suffix 'STAR' vs 'SCAR' was insufficient to distinguish the marks, especially given the identical trade channels and consumer class. The court granted an interim injunction in favour of the plaintiff while allowing defendant no. 2 a two-month period to recall existing stock from the trade.
Healthium Medtech Limited (earlier Healthium Medtech Private Limited)vsThe Registrar of Trade Marks, Chennai
Healthium Medtech Limited filed a writ petition seeking a mandamus to compel the Registrar of Trade Marks to expeditiously dispose of Opposition No. 1027536 filed by Glenmark Pharmaceuticals against Healthium's trademark application No. 4270882 for the 'Healthium' device mark in Classes 05 and 10. The petitioner complained that despite evidence having been adduced, the opposition proceedings remained pending without a final hearing. The Madras High Court allowed the writ petition and directed the Registrar to hear both parties and dispose of the opposition on merits within four weeks.
CavinKare Private LimitedvsMaha Aqua, Trading As Mahalakshmi Aqua
CavinKare Private Limited filed a trademark infringement suit against Maha Aqua (trading as Mahalakshmi Aqua) seeking a permanent injunction to restrain the defendant from using the mark 'MAA' or any deceptively similar mark in respect of goods in Class 32. The plaintiff relies on its registered trademarks 'MAA' under Nos. 1109946 and 6453733. The Court, after issues were framed and affidavits of admission/denial filed, approved a Joint Case Management Schedule suggested by both parties and set timelines for completion of evidence and oral arguments.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.